---
title: "VCANBIO: VUM02 injection for the treatment of active moderate to severe ulcerative colitis clinical trial approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/222533692.md"
description: "According to the Zhitong Finance APP, VCANBIO announced that its wholly-owned subsidiary Wuhan Guanggu VCANBIO Pharmaceutical Co., Ltd. received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration on December 16 for the use of VUM02 injection in the treatment of active moderate to severe ulcerative colitis"
datetime: "2024-12-17T09:17:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/222533692.md)
  - [en](https://longbridge.com/en/news/222533692.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/222533692.md)
generator: "portal-rs"
---

# VCANBIO: VUM02 injection for the treatment of active moderate to severe ulcerative colitis clinical trial approved

According to the Zhitong Finance APP, VCANBIO (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu VCANBIO Pharmaceutical Co., Ltd., received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration on December 16th for the use of VUM02 injection in the treatment of active moderate to severe ulcerative colitis

### Related Stocks

- [600645.CN](https://longbridge.com/en/quote/600645.CN.md)

## Related News & Research

- [10:03 ETDarkfin Labs, Founded by a Stem Cell Biologist, Brings Longevity Science to Ulta Beauty](https://longbridge.com/en/news/297798822.md)
- [Kalshi issues first lifetime ban for Republican politician over insider bets](https://longbridge.com/en/news/297684078.md)
- [California Moves to Shut Down Private Equity Takeovers of Law Firms](https://longbridge.com/en/news/297560908.md)
- [11:16 ET/C O R R E C T I O N -- Allies of Skin/](https://longbridge.com/en/news/297805717.md)
- [Zhongzi International seeks HKEX trading resumption from Sept. 1 after filing annual results](https://longbridge.com/en/news/297524727.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**